Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic liver diseases through its proprietary cyclophilin inhibitor platform. This page provides investors and industry stakeholders with timely updates on material developments including clinical trial progress, regulatory milestones, and strategic partnerships.
Our curated news feed delivers essential updates on HEPA's lead candidate CRV431, a pipeline targeting fibrosis, hepatocellular carcinoma, and viral hepatitis. Users will find verified information on Phase 2/3 trial results, FDA communications, and collaborative research initiatives without promotional bias.
The repository includes press releases covering three key areas: clinical development updates detailing patient enrollment and trial outcomes, business strategy announcements regarding licensing agreements, and scientific presentations at hepatology conferences. All content is vetted for material relevance to investment analysis and therapeutic advancement.
Bookmark this page for direct access to Hepion's latest developments in pleiotropic liver disease therapies. Check regularly for updates that may influence long-term valuation assessments in the competitive hepatology therapeutics sector.
The independent Data Safety Monitoring Board (DSMB) has approved the continuation of Hepion Pharmaceuticals' Phase 2a AMBITION clinical trial for CRV431 in NASH patients. This approval follows the successful review of the 75 mg dose cohort, which showed no safety concerns and clinically significant reductions in liver enzymes ALT and AST. The trial will now advance to a 225 mg dose cohort. Approximately 17 million people in the U.S. suffer from NASH, leading to a significant unmet medical need.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. This event will feature a series of one-on-one meetings with management. The company is focused on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, CRV431, has shown promise in reducing liver fibrosis and tumor burden in preclinical studies, with potential antiviral effects against HBV, HCV, and HDV.
Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtual findings at The Liver Meeting Digital Experience 2020, hosted by the American Association for the Study of Liver Diseases, from November 13-16, 2020. The presentation will focus on the lead drug candidate CRV431, which demonstrated superior antifibrotic efficacy against liver fibrosis compared to other NASH drug candidates in an expanded study by FibroFind. Dr. Daren Ure, Chief Scientific Officer, highlighted CRV431’s unique mechanism targeting fibrotic scar formation. The session will occur on November 13, covering various aspects of NASH treatment.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the enrollment of the last patient in the 75 mg CRV431 cohort of its Phase 2a 'AMBITION' clinical trial, focused on non-alcoholic steatohepatitis (NASH). This milestone is crucial for assessing CRV431's safety, tolerability, and early efficacy indicators. The trial will involve 18 F2 and F3 NASH patients over 28 days. Data collected will utilize Hepion's AI-POWR platform for further analysis. Anticipated results from this cohort are expected by the end of 2020, highlighting Hepion's commitment to addressing the significant healthcare burden posed by NASH.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in two virtual conferences focusing on therapeutic approaches for COVID-19 and liver diseases. On October 28, 2020, Dr. Robert Foster will present CRV431, a drug candidate with demonstrated anti-viral activity against SARS-CoV-2, during the Roth Capital Healthcare event. The following day, Hepion will discuss CRV431’s potential for treating non-alcoholic steatohepatitis (NASH) at the B. Riley Securities event. Hepion aims to highlight CRV431's broad therapeutic potential, including anti-fibrotic and anti-inflammatory effects.
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced the launch of AI-POWR™, a proprietary AI and machine learning platform aimed at improving drug development for non-alcoholic steatohepatitis (NASH). AI-POWR™ utilizes a multi-omics approach to enhance patient selection and optimize clinical trial outcomes for Hepion's lead drug candidate, CRV431, which is currently in a Phase 2a trial. The initiative is expected to reduce costs and development timelines while enhancing the likelihood of clinical success.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Dr. Robert Foster will present virtually at the H.C. Wainwright 4th Annual NASH Conference on October 5, 2020, at 4:00 p.m. E.T. The presentation will be accessible live and archived on the company’s website under the 'Events' section. Hepion focuses on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Its lead candidate, CRV431, targets liver fibrosis and exhibits antiviral properties, showcasing potential in treating various liver diseases.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive findings from a study by the National Institute of Allergy and Infectious Diseases (NIAID), showing that its drug candidate CRV431 exhibits significant antiviral activity against SARS-CoV-2. The study found CRV431 inhibited viral production with an IC90 of 1.5 μM, nearly five times more potent than a control compound. No significant cellular toxicity was observed. Hepion aims to advance CRV431 through further studies while maintaining focus on its current phase 2a program for NASH.
Hepion Pharmaceuticals announced the completion of CRV431 dosing in all subjects for its Phase 1b multiple ascending dose study. This study aimed to evaluate the safety, tolerability, and pharmacokinetics of CRV431, with doses ranging from 75 mg to 375 mg administered to healthy volunteers. The drug was well tolerated at all levels. Hepion is advancing to its Phase 2a AMBITION trial, expecting to complete the 75 mg dosing by the end of 2020. The study's outcomes are vital for further drug development targeting liver diseases like NASH.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced it will present a poster on CRV431's antifibrotic activity at the Digital International Liver Congress™ 2020 from August 27-29. Dr. Joseph Kuo will discuss a preclinical study highlighting CRV431's ability to reduce hepatic fibrosis and weight gain in a NASH mouse model. The presentation is scheduled for August 28, 2020, under poster number FRI-239. Hepion aims to develop targeted therapies for liver diseases, with CRV431 showing promise in reducing fibrosis and hepatocellular carcinoma tumor burden.
